Clinical trials: Pancreatic Ca
Solid Tumor, Adult
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
To determine the recommended phase 2 dose (RP2D) of the combination of neratinib and sodium valproate when given to patients with advanced solid tumors.
- Trial name
- NCT03919292
- Testing
- Neratinib, Divalproex Sodium
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Virginia Commonwealth University
Sepsis, Septic Shock
Nucleosome Monitoring Relevance for Outcome Prediction in Critically Ill Patients
NUROPI is a single-centre, prospective, non-interventional study in the Intensive Care Unit (ICU) of Erasme Hospital (Hôpital Universitaire de Bruxelles, Brussels, Belgium).
- Conditions
- Sepsis, Septic Shock, Cardiac Arrest (CA), Pancreatitis
- Trial name
- NuROPI (NCT07184593)
- Testing
- Plasma H3.1 nucleosome measurement
- Volunteers
- 1,000 people
- Sponsor
- Erasme University Hospital
Pancreatic Cancer
Longitudinal Pancreatic Cancer Study
To obtain sufficient specimens and correlating clinical data from a well-controlled prospective clinical trial collecting longitudinal specimens from subjects diagnosed with any stage of pancreatic cancer.
- Trial name
- NCT02250638
- Testing
- CA 19-9 Assay
- Where
- 7 sites in United States, Canada
- Volunteers
- 140 people
- Sponsor
- Fujirebio Diagnostics, Inc.
Pancreatic Cancer
Investigate Role of Metabolic Imaging in Predicting Tumor Response/Outcome After Pancreatic CA Tx
To test the ability of new imaging techniques to monitor and predict response of pancreatic cancer to radiation and/or chemotherapy.
- Trial name
- NCT00767273
- Testing
- PET Scan, FLT, FDG
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Stanford University
Stage IV Pancreatic Cancer
Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca
The investigators recently completed a phase I study of intravenous ascorbic acid (IV AA) plus standard chemotherapy (gemcitabine and erlotinib) in patients with metastatic pancreatic cancer.
- Trial name
- NCT01555489
- Testing
- Ascorbic Acid
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Thomas Jefferson University
Pancreatic Cancer, Chronic Pancreatitis
Diagnostic Utility of Protein Biomarkers in Pancreatic Ductal Adenocarcinoma
The goal of this prospective multicenter observational study is to evaluate the diagnostic accuracy of blood-based protein biomarkers for detecting pancreatic ductal adenocarcinoma (PDAC) in adults aged 18 years and older.
- Conditions
- Pancreatic Cancer, Chronic Pancreatitis, Intraductal Papillary Mucinous Neoplasm, Mucinous Cystic Neoplasm
- Trial name
- NCT07875582
- Testing
- Blood-Based Protein Biomarker Assessment
- Where
- Romania
- Volunteers
- 100 people
- Sponsor
- Grigore T. Popa University of Medicine and Pharmacy
Pancreatic Cancer
Efficacy and Safety Study of LE-DT to Treat Locally Advanced or Metastatic Pancreatic Cancer
LE-DT is a novel, proprietary delivery system of docetaxel developed by NeoPharm, Inc. Docetaxel (currently marketed as Taxotere) is an anti-microtubule agent that prevents cell division.
- Trial name
- NCT01186731
- Testing
- Liposome Entrapped Docetaxel (LE-DT)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- INSYS Therapeutics Inc
Pancreatic Cancer, Neoadjuvant
An Exploration of Candidates for Neoadjuvant Treatment in Resectable Pancreatic Cancer
An Exploration of Candidates for Neoadjuvant Treatment in Resectable Pancreatic Cancer
- Trial name
- NCT06129812
- Testing
- Neoadjuvant treatment
- Volunteers
- 1,132 people
- Sponsor
- Seoul National University Hospital
Carcinoma, Pancreatic Ductal
Predictive Factors for Resection and Survival in Type A Borderline Resectable Pancreatic Ductal Adenocarcinoma Patients After Neoadjuvant Therapy
Radical surgical resection is the only curative treatment option for pancreatic cancer, but borderline resectable tumors have a high probability of incomplete exeresis.
- Trial name
- PF-BARNA (NCT05489458)
- Testing
- Resection, No Resection
- Volunteers
- 100 people
- Sponsor
- BUSQUETS, JULI
Pancreas Cancer
Preoperative CA 19.9 Level Predicts Lymph Node Metastasis in Resectable Adenocarcinoma of the Head of the Pancreas.
In our multicenter retrospective study, preoperative CA 19.9 levels predicts the presence of lymph node metastasis at final histology in patients underwent pancreatoduodenectomy for pancreatic ductal adenocarcinoma .
- Trial name
- ICALYRA (NCT05959213)
- Volunteers
- 2,034 people
- Sponsor
- Fondazione Policlinico Universitario Campus Bio-Medico
Pancreatic Neoplasms
EUS-guided RFA for Pancreatic Neoplasms
Radiofrequency ablation has been used for treatment of solid neoplasms of the liver, lung, kidney and adrenal. Recently, EUS-guided RFA has become available and the device allows EUS-guided treatment of pancreatic neoplasms.
- Trial name
- NCT03218345
- Testing
- EUS-guided RFA
- Where
- Hong Kong
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Pancreatic Cancer, Adult, Perineural Invasion
Neutrophil-to-lymphocyte Ratio and CA 19.9 as Predictors of Perineural Invasion in Pancreatic Cancer
Pancreatic cancer has an incidence of 1,401,450 new cases diagnosed annually worldwide and is the third leading cause of cancer-related death in Spain.
- Conditions
- Pancreatic Cancer, Adult, Perineural Invasion, Neutrophil-to-Lymphocyte Ratio, CA 19.9
- Trial name
- NCT06747481
- Where
- Spain
- Volunteers
- 323 people
- Sponsor
- University of Las Palmas de Gran Canaria
Pancreatic Cancer Stage IVA
Study for Inoperable Non-Metastatic Pancreatic CA (Stage IVA) With Neoadjuvant GTX, and Radiation With Gemzar
The purpose of this study is to determine whether an experimental drug combination consisting of Gemzar®, Taxotere®, and Xeloda®, (called GTX) when followed by radiation therapy plus low-dose Gemzar, is safe and effective in…
- Trial name
- NCT00869258
- Testing
- Gemcitabine, docetaxel, and capecitabine, Radiation therapy with gemzar
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Columbia University
Colon Cancer, Pancreatic Cancer
Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers
Background: Gastrointestinal tumors have a molecule called carbohydrate antigen 19-9 (CA19-9) in the tumors and blood. The agent MVT-5873 was designed to block this molecule.
- Conditions
- Colon Cancer, Pancreatic Cancer, Cholangiocarcinoma, Metastatic Colon Carcinoma
- Trial name
- NCT03801915
- Testing
- MVT-5873, pancreatectomy or hepatectomy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Histologically or Cytologically Confirmed Pancreatic Ca, Unresectable or Borderline Resectable Pancreatic Ca
Regional Chemotherapy in Locally Advanced Pancreatic Cancer: RECLAP Trial
Background: Pancreatic cancer is difficult to treat because by the time most cases are diagnosed, the tumors are too large to be removed surgically.
- Trial name
- NCT01294358
- Testing
- Gemcitabine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Adenocarcinoma
Panc CA Risk Model & Biomarker Testing In High-Risk Cohort
The purpose of this study is to test a double screening strategy for pancreatic cancer, based on a model developed using patient medical records.
- Trial name
- NCT05287347
- Testing
- Blood Specimen
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Resectable Pancreatic Ductal Adenocarcinoma, Recurrent Pancreatic Ductal Adenocarcinoma
Recurrent Disease Detection After Resection of Pancreatic Adenocarcinoma Using a Standardized Surveillance Strategy
A randomized controlled trial, nested within an existing prospective cohort (Dutch Pancreatic Cancer Project; PACAP) and the United Kingdom (UK) Pancreas Cancer: Observations of Practice and survival; PACOPS) according to the…
- Trial name
- RADAR-PANC (NCT04875325)
- Testing
- Standardized surveillance
- Where
- 11 sites in Netherlands, United Kingdom
- Volunteers
- 306 people
- Sponsor
- UMC Utrecht
Pancreatic Cancer
PhI Study of Erbitux & Gemcitabine w/Radiation Therapy for Locally Adv. Pancreas Ca
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00467116
- Testing
- cetuximab, gemcitabine hydrochloride, radiation therapy
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Circulating Tumor Cells, Pancreatic Adenocarcinoma
Detection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma.
Histological proof is a crucial and necessary step for appropriate care in oncology. In the case of pancreatic cancer, histological proof from pathological analysis of the surgical specimen is very rare due to the limited number…
- Conditions
- Circulating Tumor Cells, Pancreatic Adenocarcinoma, Circulating Tumor DNA (KRAS), CA 19.9
- Trial name
- CTC-Pancreas (NCT02072616)
- Testing
- Pancreatic adenocarcinoma diagnosis
- Where
- France
- Volunteers
- 101 people
- Sponsor
- University Hospital, Rouen
Chronic Myeloid Leukemia (CML), Pancreatic Ca
Natural Killer Cells and Bortezomib to Treat Cancer
Natural killer (NK) cells are white blood cells that have a limited ability to kill cancer cells. This ability might be enhanced if they are given 24 hours after an injection of the drug bortezomib.
- Conditions
- Chronic Myeloid Leukemia (CML), Pancreatic Ca, Colon/Rectal Ca, Multiple Myeloma
- Trial name
- NCT00720785
- Testing
- Bortezomib, NK cells
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)